Product Code: RP-ID-10008298 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10008298
Market Overview:
Global Cell Expansion Market Outlook 2030
" The global cellular expansion market size is estimated to be valued at ~USD 21 billion by end of 2021, and the compound annual growth rate (CAGR) is expected to be 10% during the forecast period 2022-2030. The increase in the use of automated solutions in cell expansion applications is one of the market drivers. The automated system minimizes the labor and costs incurred in the production of cell therapy products (CTP), gene therapy, and other biological agents; thereby achieving a robust and reliable process.
The major players involved in the development of CTP are expanding their product lines to meet the significant increase in global demand for these therapies. For example, in March 2019, Lonza launched a comprehensive CellBio service portfolio, including the expansion of cell lines and banking services. The solution is designed to meet the requirements of research applications and ultimately accelerate market revenue generation.
The paradigm shift to single-use systems (SUS) provides huge production advantages for CTP manufacturing. SUS eliminates the concerns of cross-contamination and crop contamination caused by improper sterilization. SUS can also produce CTP with high cell density and provide long-term cost savings. Therefore, the increase in SUS applications has promoted the development of CTP, thereby driving the growth of the market.
Cell therapy is becoming more and more popular in the life science industry. Increased funding from private and government organizations and their initiatives to encourage the development of cell therapy have become market drivers. The International Stem Cell Research Association participates in identifying funding opportunities related to stem cells in biomedical research applications.
The replacement of serum and other incompatible reagents is essential to control the quality of products in CTP production. A number of studies have confirmed that the application of serum-free media controls the quality of the product. Researchers have also developed an optimization platform that combines high-throughput tools with evolution-based differential algorithms as an effective automated optimization strategy for serum-free culture formulations.
PRODUCT INFORMATION:
Consumables led the way in 2020, accounting for 45% of the total. It is expected to maintain its dominant position in the next few years. The availability of various commercial media and reagents dedicated to specific cell types contributes to the huge revenue share of this segment. In addition, these products are convenient, ready-to-use, and are also available as serum-free formulations. Due to the automation of bioreactors and other expansion platforms to improve the efficiency of the cultivation process, the instrumentation department is expected to record the fastest compound annual growth rate during the forecast period.
The emergence of an automated platform standardizes the process and makes it easier to track the process while reducing practice time; therefore, it can use the time of qualified personnel more effectively. Continued marketing and the introduction of automated planting equipment have also promoted revenue generation in the field of instruments.
For example, in March 2019, Hitachi Co., Ltd. sold its automated large-scale cell culture equipment in Japan. This commercialization allows the manufacture of induced pluripotent stem cells for regenerative medicine applications. These efforts are expected to accelerate the generation of instrument revenue.
CELL TYPE INSIGHT:
The mammalian cell segment has the highest revenue share in 2020, at 55%, and will maintain a dominant position during the forecast period because these culture systems are very popular in the production of complex protein therapies. This is because these systems have pharmacokinetic and functional relevance to the post-translational modification of the human body.
Therefore, most biopharmaceuticals, including monoclonal antibodies, specific interferons, thrombolytics, and various therapeutic enzymes, are produced using these culture systems. Differentiated human cells account for a large part of income because these cells perform specific functions in the body. Differentiated cells, such as fibroblasts, have gained immense importance in skin wound healing and skin bioengineering, thereby increasing the growth of fragments. In addition, the evaluation of 3D gingival fibroblast (GF) annulus as a feasible and simple in vitro detection method for biomaterial testing has expanded its use rate.
Human stem cells have received great attention and are expected to witness the fastest CAGR from 2022-2030. The exponential growth of research in this field and the great success of regenerative medicine are one of the key factors leading to faster growth. In addition, the implementation of automation, robotics and closed production systems in the production of clinical-grade mesenchymal stem cells is driving the development of this market segment.
APPLICATION INSIGHT:
Due to the increase in biopharmaceutical approvals in recent years, the biopharmaceutical sector has the largest revenue share in 2020, at 25%. The entry of new biopharmaceutical companies and the proliferation of bioprocessing technologies have further promoted the development of biopharmaceuticals, which in turn has promoted the expansion procedures that occur in the biological production process, and disposable technologies are gaining huge appeal.
Over the years, people have seen the introduction of alternative flat cell expansion technologies, such as compact multi-layer bioreactors. This is sufficient to meet the requirements of a closed system, limit the potential risks associated with pollution and maintain control of upstream production and large-scale unit production. In recent years, the production of cell-based vaccines. The production of these vaccines provides a cost-effective manufacturing solution while speeding up the development process.
END USE INFORMATION:
The biotech and biopharmaceutical company sector had the largest share in 2020, at 45%, and will expand further at a significant growth rate. The expanding horizons of cell-based therapies in the healthcare industry is one of the main enabling factors for most pharmaceutical companies. For example, with the continuous improvement of injectable cell delivery systems for various clinical applications, cell-based therapies have gained great popularity in regenerative medicine.
In addition, pharmaceutical and biopharmaceutical companies have also participated in acquisitions to expand their product portfolios. For example, in December 2019, Sartorius AG signed an agreement to acquire 50% of the shares of Biological Industries, a manufacturer of Israeli cell culture media. This acquisition expands Sartorius; cell culture product portfolio, especially in cell and gene therapy, regenerative medicine and other advanced therapies.
REGIONAL INFORMATION:
North America accounted for the largest share in 2020, at 42%. The region will maintain its leading position in the next few years due to increased funding programs from government agencies, which has accelerated the production and development of stem cells. Regenerative medicine and cell therapy products.
This in turn has driven the demand for cell expansion platforms in the region. For example, in October 2019, the FDA and the Medical Technology Enterprise Consortium (MTEC) provided $5.3 million in funding to the Southwest Research Institute (SwRI) (United States). SwRI invests these funds to multiply cells to develop personalized regenerative medicine.
These investments have boosted revenue generation in the region. As local pharmaceutical and biotechnology companies step up their efforts to develop and commercialize their cell therapies, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. An Indian company Stempeutics Research Pvt. Ltd. signed an alliance with Kemwell Biopharma in July 2019 to commercialize its stem cell-based product Stempeucel. It is expected that these agreements will boost the sales of SMEs.
MAJOR COMPANIES AND MARKET SHARE PROSPECTS:
Major market participants are taking various measures to expand their market share and maintain a competitive advantage in this field. In addition, they are also involved in cooperation and partnership models, product development, agreements and business expansion strategies in undeveloped areas. For example, in June 2019, Demcon acquired a stake in cell therapy manufacturer Scinus Cell Expansion BV. Mother cell. The team is located in the Netherlands.
This acquisition helped Sinus expand its business into the stem cell therapy market. Such growth measures are expected to increase the utilization rate of bioreactors used to cultivate stem cells, thereby promoting market growth. Some of the major players in the cell expansion market include: Thermo Fisher Scientific, Inc. GE Healthcare Corning, Inc. STEMCELL Technologies, Inc. Merck KGaAMiltenyi BiotecBecton, Dickinson and Company Terumo Bct, Inc. Sartorius AG Takara Bio, Inc. Trinova Biochem GmbHupcyte Technology Co., Ltd
MARKET SEGMENTS COVERED BY THE REPORT :
This report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each market segment from 2022-2030. For the purpose of this research, Kenneth Research has subdivided global cell expansion based on product, cell type, application, end use, and regional market report: product outlook (revenue, millions of dollars, 2022-2030) consumables, reagents, Culture media and serum, other consumables, culture flasks and accessories, tissue culture flasks, bioreactor accessories and accessories, automatic cell expansion systems, cell counters, centrifuges, bioreactors, and other instruments, cell type perspective (revenue, millions of dollars, 2022-2030), breastfeeding Animal Human Stem Cells (CS) Adult CSsPully-derived embryonic drug ClepiPharmaceuticals DevelopersDifferentiated Pharmaceutical CellsCells of different pr Biopharmaceutical production 20 Microorganisms 27 Therapies Cancer research Stem cell research Other end-use prospects (Revenue, USD million, 2022-2030) Biopharmaceuticals and biotechnology Company Research Institution Cell Bank Others. "
1. Thermo Fisher Scientific, Inc.
2. GE Healthcare (A Wholly Owned Subsidiary of General Electric Company)
3. Lonza Group Ltd.
4. Becton, Dickinson and Company
5. Corning, Inc.
6. Merck KGAA
7. Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
8. MiltenyiBiotec
9. Stemcell Technologies
10. Terumo BCT, Inc. (A Subsidiary of Terumo Corporation)
Related Reports
Proof of Quality & Reliability
